GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in iPSC-based cell therapy (induced pluripotent stem cells). Its stock price is a venture bet on the success of its revolutionary scientific platform. The chart reflects high volatility associated with clinical trial news.
Share prices of companies in the market segment - Cancer cure
Fate Therapeutics is a biopharmaceutical company developing induced pluripotent stem cell-based immunotherapy for the treatment of cancer. We classify it in the "Cancer Treatment" sector. The chart below shows the overall dynamics of this cutting-edge medical field.
Broad Market Index - GURU.Markets
Fate Therapeutics is a pioneer in developing induced pluripotent stem cell (iPSC)-based cell therapies for the treatment of cancer and immune disorders. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
FATE - Daily change in the company's share price Fate Therapeutics Inc.
For Fate Therapeutics, Inc., a cell therapy company, daily price change is a measure of extreme volatility. It reflects the market's reaction to research data and is a critical parameter in risk assessment formulas for innovative biotech companies.
Daily change in the price of a set of shares in a market segment - Cancer cure
Fate Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with FATE, a pioneer in cell therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Fate Therapeutics is a pioneer in the development of cell therapy based on induced pluripotent stem cells. The company's shares move in sync with scientific discoveries and clinical data. This high, innovation-driven volatility is part of the dynamics of the entire biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Fate Therapeutics Inc.
For Fate Therapeutics, the year-over-year performance tells the story of its strategic pivot to cell therapy development. Its market cap change over the past 12 months reflects the company's decision to cut costs and focus on its most promising programs based on induced pluripotent stem cells (iPSCs) following the end of its partnership with Janssen.
Annual dynamics of market capitalization of the market segment - Cancer cure
Fate Therapeutics, Inc. is a biotechnology company pioneering the development of induced pluripotent stem cell-based therapies. Its stock price is highly volatile, reflecting investor confidence in its breakthrough scientific potential rather than its current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fate Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of iPSC-based cell therapies. Its monthly performance reflects the progress and setbacks in this cutting-edge but risky field. Clinical trial data and news about strategic decisions regarding its development pipeline drive sharp and strong movements in its stock.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of cellular immunotherapies based on induced pluripotent stem cells (iPSCs). This enables the creation of ready-to-use cancer treatments. The graph below shows the dynamics of the biotech sector, where such platform technologies have the potential to revolutionize medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fate Therapeutics is a pioneer in the development of cell therapy based on induced pluripotent stem cells. The company's stock is at the forefront of biotech innovation. Its performance is entirely dependent on clinical trial results, and any success or failure causes sharp movements, ignoring the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Fate Therapeutics Inc.
Shares of Fate Therapeutics, a pioneer in NK cell-based cell therapy, reflect the hopes and risks in oncology on a weekly basis. Price movements reflect clinical trial data that could confirm the potential of their "off-the-shelf" cell therapy products.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Fate Therapeutics is a pioneer in developing cell therapy based on induced pluripotent stem cells (iPSCs). This is cutting-edge, but highly risky, science. The chart will reveal whether Fate's weekly share price fluctuations are driven by its unique scientific data or reflect overall investor sentiment toward the entire cell therapy sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Fate Therapeutics is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Fate exist in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
FATE - Market capitalization of the company Fate Therapeutics Inc.
Fate Therapeutics' market capitalization chart tells the dramatic story of a pioneer in iPSC-based cell therapy (induced pluripotent stem cells). Its collapse signals the end of a partnership with a major pharmaceutical company and a rethinking of its entire strategy. This dynamic is a clear example of how quickly prospects can change in biotech.
FATE - Share of the company's market capitalization Fate Therapeutics Inc. within the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of "off-the-shelf" cellular immunotherapies based on induced pluripotent stem cells (iPSCs). Its market capitalization reflects both the enormous potential of this platform and the development risks. The chart below shows how the market views its chances of creating a new standard in cell therapy.
Market capitalization of the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of cell therapy based on induced pluripotent stem cells. The chart below shows the market capitalization of this cutting-edge sector. Its extreme volatility speaks volumes about the revolutionary potential of this technology and the enormous risks associated with its clinical development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Fate Therapeutics is a pioneer in cell therapy using induced pluripotent stem cells. Its capitalization is a bet on a revolutionary technology that promises to create ready-to-use cell therapies. Its momentum is the pulse of one of the most futuristic fields in medicine.
Book value capitalization of the company, segment and market as a whole
FATE - Book value capitalization of the company Fate Therapeutics Inc.
Fate Therapeutics' balance sheet represents its capital invested in the development of "off-the-shelf" cell therapy (iPSC-derived NK and T cells) for cancer treatment. This is the real, scientific foundation for creating universal cell-based medicines. How has this pioneering, yet risky, asset evolved? The chart below tells its dramatic story.
FATE - Share of the company's book capitalization Fate Therapeutics Inc. within the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of iPSC-based (induced pluripotent stem cell) cell therapies. The chart shows the proportion of its unique manufacturing and laboratory assets, reflecting the physical foundation of this cutting-edge biotechnology.
Market segment balance sheet capitalization - Cancer cure
Fate Therapeutics is a leader in cell therapy development. This cutting-edge science doesn't require massive manufacturing facilities at the R&D stage. The book value chart shows how "light" the company's capital base is, with the potential hidden in its technologies.
Book value of all companies included in the broad market index - GURU.Markets
Fate Therapeutics is a pioneer in the development of cell therapies from induced pluripotent stem cells. Its book value represents its advanced manufacturing facilities and laboratories. The chart shows the physical scale of the infrastructure required to create "off-the-shelf" living cancer drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Fate Therapeutics Inc.
Fate Therapeutics' balance sheet is based on laboratories. But the market sees it as a leader in cell therapy. The chart shows a colossal "hope factor": a premium for its unique platform capable of creating universal "living cures" for cancer.
Market to book capitalization ratio in a market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapies. Its value lies in its revolutionary scientific platform. The chart demonstrates the enormous investor expectations for its ability to create "off-the-shelf" cell therapies.
Market to book capitalization ratio for the market as a whole
Fate Therapeutics is a pioneer in developing cell therapies based on induced pluripotent stem cells (iPSCs). This technology enables the creation of "ready-to-use" cell therapies. This chart shows the overall valuation, but how does the market value a company trying to create a renewable source of cells for cancer treatment?
Debts of the company, segment and market as a whole
FATE - Company debts Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in cell therapy. This chart reflects the company's enormous financial needs. It is raising significant capital to fund its revolutionary research into creating "off-the-shelf" cell therapies, which could revolutionize cancer treatment.
Market segment debts - Cancer cure
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapies, enabling the creation of "off-the-shelf" cell therapies. This chart shows how the company is raising the significant capital needed to develop this revolutionary but complex platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of cell therapy based on induced pluripotent stem cells. This chart shows how the company finances its revolutionary, but extremely expensive, research. The level of debt here is a measure of the financial risk in the pursuit of universal, "off-the-shelf" cell therapies for cancer.
Market segment debt to market segment book capitalization - Cancer cure
Fate Therapeutics is developing cellular immunotherapy based on induced pluripotent stem cells. This chart illustrates the financial leverage in the cutting-edge cell therapy sector. It provides insight into how the industry as a whole finances its capital-intensive developments and how Fate's strategy, with its unique platform, compares to this backdrop.
Debt to book value of all companies in the market
Fate Therapeutics is a pioneer in the development of cell therapy based on induced pluripotent stem cells. This is one of the most advanced and capital-intensive areas of biotech. A graph of the economy's total debt burden only underscores that Fate's financial model is a pure venture capital bet on science, having nothing in common with traditional lending.
P/E of the company, segment and market as a whole
P/E - Fate Therapeutics Inc.
This valuation multiple for Fate Therapeutics, a leader in developing iPSC-based (induced pluripotent stem cell) cell therapies, reflects the valuation of its breakthrough platform. The multiple reflects investors' belief that its approach will enable the creation of commercially viable cell-based therapies for cancer treatment.
P/E of the market segment - Cancer cure
Cell therapy, a field in which Fate Therapeutics was a pioneer, is a high-risk business. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Fate, after clinical setbacks, is being evaluated based on the potential of its remaining programs and its ability to restore investor confidence.
P/E of the market as a whole
Fate Therapeutics, Inc. is a pioneer in developing cell therapies based on induced pluripotent stem cells (iPSCs), enabling the creation of "off-the-shelf" cancer treatments. This revolutionary approach is a breakthrough. This biotech sentiment chart helps understand how the market is pricing this complex but potentially game-changing technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Fate Therapeutics Inc.
Fate Therapeutics is a biotech company developing cellular immunotherapies based on induced pluripotent stem cells. This graph reflects expectations for its revolutionary platform for creating "ready-to-use" cell-based cancer therapies. The trend is an assessment of its scientific potential.
%20P%2FE%20Fate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Fate-Therapeutics-Inc.&v=1772666736060 "Chart of the company's future (projected) P/E Fate Therapeutics Inc.")
Future (projected) P/E of the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapies, creating off-the-shelf cancer treatments. This chart shows the expected profitability of the sector, helping to understand how highly the market values this breakthrough technology platform and its potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772666736108 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Fate Therapeutics, Inc. is a clinical-stage biotech company developing induced pluripotent stem cell-based immunotherapy for the treatment of cancer. This chart shows investor risk appetite. For a company operating at the forefront of cell technology, it reflects the market's willingness to fund breakthrough scientific platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772666736152 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Fate Therapeutics Inc.
Fate Therapeutics, Inc. is a biotechnology company pioneering the development of induced pluripotent stem cell (iPSC)-based cell therapies. The financial results shown here represent investments in the development of standard cell therapy. The graph shows the cost of developing a revolutionary cancer treatment platform.
Profit of companies in the market segment - Cancer cure
Fate Therapeutics is a pioneer in developing "ready-to-use" cellular immunotherapies based on induced pluripotent stem cells (iPSCs). This approach has the potential to make cell therapy more accessible. This chart illustrates how breakthrough scientific platforms like Fate's can transform the future of medicine and define new horizons of profitability in biotech.
Overall market profit
Fate Therapeutics is a pioneer in the development of cell therapies based on induced pluripotent stem cells. This is one of the most advanced fields in medicine. The company's success depends on scientific breakthroughs. This overall market return chart provides the backdrop against which investors decide whether they are willing to fund such fundamental, yet risky, scientific endeavors.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Fate Therapeutics Inc.
Fate Therapeutics is a biotech company developing induced pluripotent stem cell (iPSC)-based cell therapies for the treatment of cancer. The earnings forecast in this chart reflects analysts' expectations for its cutting-edge scientific platform.
%20profit%20of%20the%20company%20Fate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Fate-Therapeutics-Inc.&v=1772666736293 "Graph of future (projected) profit of the company Fate Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Fate Therapeutics is a pioneer in developing induced pluripotent stem cell (iPSC)-based cellular immunotherapies, creating "off-the-shelf" cancer treatments. This chart shows the revenue forecast for the cancer treatment sector, allowing one to assess the market's perception of the potential of Fate's revolutionary yet complex technology platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772666736341 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Fate Therapeutics is a biotech company developing cell therapy. Its future depends on the success of clinical trials. This chart, reflecting market sentiment, influences investor willingness to invest in capital-intensive and risky projects in advanced medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772666736352 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapies. This graph shows a speculative estimate of its future potential. This estimate is a bet that its "off-the-shelf" cell therapy will revolutionize cancer treatment.
P/S market segment - Cancer cure
Fate Therapeutics is a pioneer in developing induced pluripotent stem cell (iPSC)-based cancer immunotherapy. This chart shows the biotech industry average market capitalization to revenue ratio. It reflects the premium investors are willing to pay for the potential of this advanced platform for creating "ready-to-use" cell therapies.
P/S of the market as a whole
Fate Therapeutics is a biotech company pioneering the development of induced pluripotent stem cell (iPSC)-based cell therapies for the treatment of cancer and immune disorders. This chart helps understand how the market values companies creating entire technology platforms that have the potential to revolutionize medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of cellular immunotherapies based on induced pluripotent stem cells (iPSCs). This chart shows the company's valuation relative to its hypothetical future sales. It reflects investors' faith in its revolutionary platform for creating "off-the-shelf" cell therapies.
%20P%2FS%20Fate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Fate-Therapeutics-Inc.&v=1772666736520 "The graph of the company's future (projected) P/S Fate Therapeutics Inc.")
Future (projected) P/S of the market segment - Cancer cure
Fate Therapeutics is a clinical-stage biotechnology company pioneering the development of induced pluripotent stem cell (iPSC)-based cellular immunotherapies. This chart reflects investor expectations for its breakthrough scientific platform and potential future revenue.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772666736570 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Fate Therapeutics is a biotech company developing cellular immunotherapy based on induced pluripotent stem cells. Its future depends entirely on the success of its scientific platform. This graph of overall expectations for FATE is merely a backdrop. The company's value is determined by faith in its breakthrough technology, not the overall economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772666736687 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Fate Therapeutics Inc.
This chart illustrates the financial trajectory of a biotech company. For Fate Therapeutics, a pioneer in induced pluripotent stem cell-based cell therapy, it reflects revenue from collaborations with partners to develop its innovative cancer treatments.
Sales of companies in the market segment - Cancer cure
Fate Therapeutics is a pioneer in developing cell therapies based on induced pluripotent stem cells (iPSCs). This technology enables the creation of "off-the-shelf" cancer treatments. This graph shows revenue in oncology. The success of Fate's platform has the potential to revolutionize cell therapy, making it more accessible and scalable.
Overall market sales
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapy. This is one of the most advanced technologies in medicine. The company's success could lead to the creation of "off-the-shelf" cell therapies for the treatment of cancer and other diseases, revolutionizing healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cell therapies, creating ready-to-use cancer treatments. Future sales projections depend on the success of this cutting-edge and sophisticated technology.
%20sales%20of%20the%20company%20Fate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Fate-Therapeutics-Inc.&v=1772666736954 "Schedule of future (projected) sales of the company Fate Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Fate Therapeutics, Inc. is a pioneer in the development of cell therapies based on induced pluripotent stem cells (iPSCs). The forecast for the cancer treatment and cell therapy sector highlights expectations for "off-the-shelf" solutions. The graph reflects the potential for creating universal cell therapies that do not require custom manufacturing.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772666737009 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Fate Therapeutics is a biotech company developing cellular immunotherapies for the treatment of cancer and immune disorders. Its prospects depend on the success of clinical trials. This overall economic activity schedule does not affect its scientific activities, but it does shape the overall investment climate and influence the cost of raising capital for research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772666737139 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Fate Therapeutics Inc.
Fate Therapeutics is a biotech company pioneering the development of induced pluripotent stem cell (iPSC)-based cell therapies. While in the R&D stage, it incurs significant costs. This chart illustrates the investment in its cutting-edge scientific platform, which represents the price of developing potentially revolutionary treatments.
Market segment marginality - Cancer cure
Fate Therapeutics is a biotechnology company pioneering the development of induced pluripotent stem cell (iPSC)-based cell therapies. Its profitability depends on the success of this cutting-edge platform. This reflects its operational structure and significant investment in research compared to other cell therapy companies.
Market marginality as a whole
Fate Therapeutics, Inc. is a clinical-stage biotechnology company developing cellular immunotherapy based on induced pluripotent stem cells. This chart shows the company's overall profit margin. Compared to this, Fate is a story of cutting-edge science. The company is unprofitable and is investing in the creation of "off-the-shelf" cell therapies, which could change the market.
Employees in the company, segment and market as a whole
Number of employees in the company Fate Therapeutics Inc.
Fate Therapeutics is a pioneer in the development of cellular immunotherapies based on induced pluripotent stem cells (iPSCs). Its team of scientists and manufacturing specialists is its greatest asset. The dynamics in this chart reflect its scientific progress. This growth is driven by the expansion of clinical trials of its "off-the-shelf" cell products.
Share of the company's employees Fate Therapeutics Inc. within the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of induced pluripotent stem cell (iPSC)-based cellular immunotherapies. This chart demonstrates its scientific leadership. It reflects the significant number of leading biologists and cell engineers working on this revolutionary "ready-to-use" cell platform that Fate brings together.
Number of employees in the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of cell therapies based on induced pluripotent stem cells (iPSCs). This graph illustrates breakthrough technologies in regenerative medicine. The growth of the scientific team here signifies progress in the creation of "off-the-shelf" cell therapies that can be mass-produced and made more accessible to patients.
Number of employees in the market as a whole
Fate Therapeutics, Inc. is a pioneer in cell therapy using induced pluripotent stem cells. They are at the cutting edge of science. The overall economic situation reflected in this chart is irrelevant to them. Their market capitalization and staff grow or shrink depending on the results of clinical trials and strategic partnerships.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Fate Therapeutics Inc. (FATE)
Fate Therapeutics is a leader in developing cell therapies based on induced pluripotent stem cells (iPSCs). This enables the creation of "off-the-shelf" cancer treatments. This chart shows how the market values breakthrough platforms. The astronomical market capitalization per employee reflects the potential of their technology to create a new standard in cell therapy.
%20of%20the%20company%20Fate%20Therapeutics%20Inc.%20(FATE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Fate-Therapeutics-Inc.-FATE&v=1772666737809 "Chart of market capitalization per employee (in thousands of dollars) of the company Fate Therapeutics Inc. (FATE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Fate Therapeutics is a pioneer in the development of iPSC-based cell therapy, one of the most complex and promising areas in biotech. This chart shows the colossal premium the market is willing to pay for the company's scientific potential. Each scientist there is working on technology that could be worth tens of billions of dollars.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772666737920 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Fate Therapeutics is a biotech company pioneering the development of induced pluripotent stem cell (iPSC)-based cell therapies. This chart shows a high employee valuation, as its platform can enable the creation of "off-the-shelf" cell therapies for cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772666737999 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Fate Therapeutics Inc. (FATE)
Fate Therapeutics is a biotech company pioneering the development of iPSC-based (induced pluripotent stem cell) cell therapies. They create off-the-shelf cell-based cancer treatments. This is cutting-edge R&D. This negative figure reflects the enormous cost of research per scientist in this revolutionary field.
%20Chart%20Fate%20Therapeutics%20Inc.%20(FATE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Fate-Therapeutics-Inc.-FATE&v=1772666738034 "Company Profit Per Employee (in thousands of dollars) Chart Fate Therapeutics Inc. (FATE)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Fate Therapeutics (FATE) is a clinical-stage biotech company, a pioneer in the field of iPSC cell therapy. For them, this industry-standard chart is a distant goal. At the R&D stage, profitability is negative. FATE's success will mean that their scientific team has created a platform that will deliver financial returns multiples higher than the current average.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772666738164 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Fate Therapeutics (FATE) is a pioneer in the field of iPSC cell therapy, one of the most advanced and complex sectors of biotech. The company is in the R&D stage. Its negative earnings per employee reflects the enormous investment in its scientific team, which is working to create "test tube drugs" for cancer treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772666738244 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Fate Therapeutics Inc. (FATE)
Fate Therapeutics is a pioneer in induced pluripotent stem cell therapy. This chart reflects its status as an R&D company. Lack of revenue is normal. This metric demonstrates potential: a successful product can generate enormous revenue with a small research staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Fate-Therapeutics-Inc.-FATE&v=1772666738304 "Sales chart per company employee Fate Therapeutics Inc. (FATE)")
Sales per employee in the market segment - Cancer cure
Fate Therapeutics is a pioneer in developing iPSC-based cell therapies (induced pluripotent stem cells), creating ready-to-use NK and T cells. At the R&D stage, this metric reflects how effectively their scientific team generates revenue (e.g., from partnerships) by advancing this highly complex technological platform.
Sales per employee for the market as a whole
Fate Therapeutics is a clinical-stage biotech company, a pioneer in the development of iPSC-based (induced pluripotent stem cell) therapies for cancer treatment. It is a 100% R&D company. This chart shows revenue per employee, which, as expected, is zero. It emphasizes that the company doesn't sell products but rather invests in science.
Short shares by company, segment and market as a whole
Shares shorted by company Fate Therapeutics Inc. (FATE)
Fate Therapeutics is a pioneer in developing iPSC-based (induced pluripotent stem cell) cell therapies, creating off-the-shelf NK and T cells. This chart highlights bearish bets. Bears may question the efficacy of this complex technology compared to autologous CAR-T therapy or its safety, which is a key risk.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Fate-Therapeutics-Inc.-FATE&v=1772666738477 "Short Shares Chart for the Company Fate Therapeutics Inc. (FATE)")
Shares shorted by market segment - Cancer cure
Fate Therapeutics is a pioneer in developing cell therapies based on induced pluripotent stem cells (iPSCs). This chart shows overall short positions in the cell therapy sector. High values reflect investor doubts about the technology across the industry, anticipating challenges with production or the effectiveness of such complex treatments.
Shares shorted by the overall market
Fate Therapeutics (FATE) is a clinical-stage biotech company working in cell therapy. Its survival depends on access to funding. When this market pessimism rises, the window for raising capital slams shut. Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Fate Therapeutics Inc. (FATE)
Fate Therapeutics is a biotech company focused on cell therapy. The stock is extremely volatile after setbacks. A chart above 70 may reflect rare positive R&D news or speculative interest. A level below 30 is often associated with further setbacks, funding concerns, or a general downturn in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Fate-Therapeutics-Inc.-FATE&v=1772666738664 "RSI 14 indicator chart for the company's stock Fate Therapeutics Inc. (FATE)")
RSI 14 Market Segment - Cancer cure
Fate (FATE) — "CAR-T" 2.0 (iPSC). They are *NK* (natural killer) cell "engineers" — creating a "universal" (off-the-shelf) cancer cure. The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is FATE's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
For Fate Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FATE (Fate Therapeutics Inc.)
Fate Therapeutics is a biotech company specializing in the development of allogeneic (off-the-shelf) cell therapies (iNK, iT) for the treatment of cancer. This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential of their iPSC platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FATE-Fate-Therapeutics-Inc.&v=1772666738858 "A chart showing analyst consensus forecasts for the expected stock price. FATE (Fate Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price FATE (Fate Therapeutics Inc.)
Fate Therapeutics is a pioneer in developing "universal" cell therapy (iPSC) for cancer treatment. Their goal is to create T-cells from stem cells "for future reference." This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this highly sophisticated scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FATE-Fate-Therapeutics-Inc.&v=1772666738939 "A chart showing the difference between the consensus forecast and the actual stock price. FATE (Fate Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Fate Therapeutics is a pioneer in cell therapy. The company develops off-the-shelf NK cells (iPSCs) that can be used to treat cancer without a donor. This chart reflects the general expectations of oncology analysts, demonstrating whether experts believe in the future of "universal" cell therapy.
Analysts' consensus forecast for the overall market share price
Fate Therapeutics (FATE) is a pioneer in cell therapy. They develop off-the-shelf NK cells from stem cells (iPSCs) for cancer treatment. This is incredibly complex science. This chart shows the overall risk appetite. It reflects the willingness of investors to fund breakthrough, but extremely expensive and risky, R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Fate Therapeutics Inc.
Fate Therapeutics is a pioneer that fell from grace. They were leaders in the development of universal (allogeneic) cell therapy (iPSC), but collapsed after an R&D partnership collapsed. This chart is a summary of their resurgence. It reflects their desperate attempts to salvage their R&D platform, their remaining cash, and the market's skepticism about their second chance.
AKIMA Market Segment Index - Cancer cure
Fate Therapeutics is a pioneer in the development of off-the-shelf (allogeneic) cell therapy based on induced pluripotent stem cells (iPSCs) for cancer treatment. This chart shows the average index for the cell therapy sector. It provides investors with a benchmark for how Fate, with its breakthrough but risky technology, compares to the average.
The AKIM Index for the overall market
Fate Therapeutics is a leader in developing iPSC-based (induced stem cell) immunotherapy for cancer treatment. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this cutting-edge, yet capital-intensive, scientific platform.
